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Abstract 
 
The Quest for Quality scheme was introduced with the aim of reducing hospital admission 
rates from care homes through interventions conducted by a multidisciplinary team (MDT). 
The objective of this was to study the types of interventions being made and establish their 
impact. The data was collected directly by the MDT prior to the research and therefore the 
analysis was retrospective. Exclusion criteria were set for each part of the analysis, taking 
into account missing data. A flow chart based on situations was developed allowing 
interventions to be classified into British National Formulary (BNF) categories and then 
assigned a priority. The categories found to have the most interventions were related to the 
gastrointestinal system (140) and to nutrition and blood (128), findings that were anticipated 
due to the medical issues arising in the elderly. One of the major problems identified was in 
the follow-up of interventions. Overall, 35% of intervention outcomes were unknown and only 
20% were actioned. Reasons given for this were issues with patient record systems and the 
interventions not being received by the prescriber; a system allowing interventions to be 
tracked was therefore suggested. The causation between increasing reviews and decreasing 
hospitalisations could not be proved (Pearson correlation=−0.983, CI 95%) due to 
insufficient data. It was, however, shown that the MDT were making appropriate and 
valuable interventions, contributing to a reduction in polypharmacy and better quality of care 
when taking into account the specific case studies identified. With Quest for Quality now 
recommissioned, it will continue to make improvements to the benefit of patients. 
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Introduction 
 
With emergency admission rates to hospital being higher for the residents of care homes 
than for the general population (Calderdale Clinical Commissioning Group, n.d.), it is 
important to recognise and improve the quality of care for these patients. Owing to the 
nature of patients in this setting, these residents have complicated needs and are taking 
many different medications. The risk of inappropriate prescribing, interactions and adverse 
drug events is, therefore, high in this population and strategies can be employed to improve 
the quality of care they receive. To solve this problem, a multidisciplinary approach is 
needed, putting the patient at the centre of care and incorporating a partnership approach 
with care homes and social care professionals (British Geriatrics Society, 2011).  
 
In 2012, NHS Calderdale Clinical Commissioning Group implemented Quest for Quality, a 
scheme involving the use of telecare health systems, allowing real-time access to live clinical 
records, and a multidisciplinary team (MDT) to review patients and make interventions. The 
purpose of this pilot was to improve care quality for residents and to reduce avoidable visits 
to hospitals and GPs (Smith, Sherlaw-Johnson, Ariti, & Bardsley, 2015).  
 
The study outlined in this paper aimed to evaluate the impact that the involvement of an 
MDT has made on the quality of care for residents of care homes in the Calderdale area. 
The study set out to classify the types of interventions made by the MDT and evaluate the 
proportion of harm minimisation in order to determine whether the inclusion of an MDT in the 
Quest for Quality scheme has made a significant difference in quality of care, and to assess 
the contribution of the Quest pharmacist in the MDT.  
 
This was achieved through a review of the data collected from the date of implementation in 
May 2014 until August 2015, with the objective of determining the impact that the MDT has 
had on the quality of care. After classifying the interventions made by the health care 
professionals, the level of harm minimisation was evaluated for each individual patient and 
collated along with the contribution that the pharmacist has made in the MDT. 
 
Literature review  
 
There are long-standing and well-documented issues regarding the quality of care in care 
homes, including the use of multiple medicines and the NHS resources shared between the 
433,000 (Laing, 2015) people living in residential care. Quality Watch, an independent body 
analysing the quality of health and social care, has worked to fill a gap in research 
concerning this population (Smith, Sherlaw-Johnson, Ariti, & Bardsley, 2015). Primary 
analysis showed that 79.7% of emergency admissions of patients over the age of 75 
originated from care homes, including for conditions such as dementia, mental health 
problems and epilepsy. The report concluded that admission rates were increased in 
patients over 75 years of age and implied that there were increased chances of emergency 
admission from care homes due to complicated conditions. 
 
The Department of Health aimed to establish the cause and types of medication errors 
(Alldred et al., 2011), dividing them into prescribing, monitoring, dispensing and 
administration of medicines. The results showed that each patient was taking a mean of 7.2 
medicines, with 69.5% of the patients having at least one error. Another report, using a 
variety of data collection methods, found that each patient was on an average of 8 
medications, with an average of 1.9 errors per patient (Barber et al., 2009).  
 
Previous projects 
The Applied Health and Wellbeing Partnership conducted a pilot study of care quality in care 
homes in the Wirral Community Trust (Hughes & Timpson, 2013). This report recognised 
that with an ageing population there is a need for the advancement and improvement of care 
when using an out-of-hours GP and an MDT. There were similarities to Quest for Quality, 
although telecare health was not included; this showed that a previous pilot has been 
successful, which justifies the benefit of the scheme. 
 
Results of interventions made in care home settings 
Gurwitz et al. (2000) studied the incidence and preventability of adverse drug reactions 
(ADRs) in nursing homes. They identified 546 ADRs, with 51% concluded to be preventable 
and 308 to be significant (P < 0.001). Although it took into account data from only one area, 
this study demonstrates the need for a scheme such as Quest for Quality. 
 
Impact on care quality of the inclusion of pharmacy in MDTs  
Zermansky et al. (2006) evaluated the contribution of the pharmacist in a review of 
medications, and the outcomes of this included a reduction in fall risk. The pharmacist’s 
interventions were compared to the control group who were reviewed by a GP, and although 
the methodology was limited due to time and confidentiality issues, it was concluded that a 
pharmacist-led intervention reduces fall risk. 
 
Guidelines for prescribing safely in the elderly 
The Stopp/Start toolkit is one of the primary reference sources used in the care of the elderly 
to support medication reviews and appropriate prescribing, allowing medications to be 
stopped and more appropriate ones started (NHS Cumbria, 2013). The resource was 
developed by 18 experts in geriatric pharmacology, based on statistical analysis and local 
guidance. 
 
The All Wales Medicines Strategy Group has provided guidance on polypharmacy and 
prescribing for frail adults (Jones, Bevan, & Pugh-Jones, 2014). This work aimed to 
document and resolve current issues in prescribing for the elderly, while taking into account 
that guidelines often focus on the initial treatment and not withdrawal. In addition to specific 
medication suggestions, such as reducing anticholinergic side effects, the report gives 
solutions, such as simplifying the dosage regime, discussing long-term side effects and 
offering appliance aids. 
 
One issue commonly encountered in the elderly, polypharmacy, is the subject of much 
guidance. The Model of Care Polypharmacy Working Group for NHS Scotland (2012) aimed 
to provide a national approach to adverse drug reactions; suggestions include stopping 
Angiotensin Converting Enzyme (ACE) inhibitors and Non-Steroidal Anti-inflammatory Drugs 
(NSAIDS) in dehydrated patients and seeking specialist advice before starting medications 
such as Amiodarone and Disease-Modifying Antirheumatic Drugs (DMARDs). Reducing 
polypharmacy can be achieved by withdrawing medication in the patient; Scott, Gray, Martin, 
Pillans, and Mitchell (2012), who reported on the evidence for deprescribing in older 
populations, described the process of tapering, withdrawing and discontinuing medications. 
They found evidence supporting a structured approach to drug discontinuation, providing 
that the correct strategies are in place. 
 
Common clinical issues and prescription errors in care home patients 
Elderly patients are commonly taking complicated multidrug regimes, which have a higher 
potential for interactions and ADRs. Polypharmacy is a widespread problem and a known 
challenge to the pharmacological management of patients. In a report on deprescribing, 
Gnjidic, Le Couteur, Kouladjian, and  Hilmer  (2012) defined polypharmacy as the use of five 
or more medications. A report by the Kings Fund (Duerden, Avery, & Payne, 2013) 
described polypharmacy as being both problematic and beneficial therapeutically. It may 
increase drug interactions and decrease medication adherence, but, on the positive side, it 
can improve the outcomes for patients and increase quality of life. One of the main 
outcomes was that the rationale for treatment choice should be clearly stated, and those 
choices that do not follow an evidence base should be recorded.  
 
Intervention classification and tools for analysis 
To analyse the outcomes of interventions, a number of analytical techniques and 
classifications can be used. A report to the Patient Safety Research Portfolio (Alldred et al., 
2011) used a harm-minimisation scale. The scale assigned a number between 0 and 10, 
where a score of 0 would mean no harm and a score of 10 would mean death. Alldred et al. 
suggested a further way to separate and classify interventions, namely by the four main 
types of medication errors: prescribing, monitoring, dispensing or administration. A third 
method for classifying interventions was described by Barker et al. (2002), where medication 
errors were witnessed by observation; they were verified by a research pharmacist and the 
clinical significance of each was classified, which may be considered subjective to the 
opinion of the health professionals involved.  
 
To analyse the impact of the Quest for Quality scheme, interventions would have to be 
categorised in order to allow statistical analysis to be performed. 
 
The Quest for Quality scheme 
Primary statistical analysis conducted by the Calderdale Clinical Commissioning Group 
(CCG) (n.d.) already shows improvement in the quality of care. For example, emergency 
hospital admissions have been reduced by 25% annually and GP visits to Quest care homes 
have been reduced by 58%. 
 
Methodology 
 
Materials and methods 
The analysis was conducted retrospectively after the data was collected directly by the MDT 
across the 31 Quest care homes over a period of 17 months. After discussion of each 
patient during the reviews, the outcome was noted and then followed up at a later date by 
the MDT. The data collected included the care home and the GP surgery, interventions 
made, NHS number if available, and follow-up details. Ethical approval to undertake this 
analysis was received from the university along with Calderdale and Huddersfield NHS 
Foundation Trust. After the data was received, analysis was conducted using Microsoft 
Excel and the IBM SPSS software package.  
 
Exclusion criteria 
Some of data collected by the MDT had values missing, so certain records were excluded 
from the analysis for the following reasons: 
 
1. The medication name was not listed, meaning the priority of the intervention could 
not be assessed. 
2. No NHS number was included, so it could not be determined whether the data came 
from the same patient, therefore giving the possibility of skewed results.  
3. There were fewer than five reviews conducted in one month. 
 
If follow-up of the intervention was not included, results could still be used to assess the 
short-term effectiveness of the MDT’s intervention. Therefore, all the remaining data after the 
initial exclusion criteria was used in the analysis. 
 
Categorisation of data 
Before analysis, the exclusion criteria were applied and the 803 interventions remaining put 
into one of the following groups, according to the mode of action and classification in the 
British National Formulary (BNF): Antibiotics; Cardiovascular; Central Nervous System; Ear, 
Nose and Oropharynx; Endocrine; Eye; Gastrointestinal; Musculoskeletal and Joint; Nutrition 
and Blood; Obstetrics, Gynaecology and Urinary Tract Disorders; Respiratory; and Skin. 
Each intervention was then classified as either high priority, medium priority or low priority. In 
order to accurately and consistently identify which interventions were high or low priority, a 
flow chart was devised (Figure 1). For example, in a high-priority case, the intervention 
would need to be implemented immediately and followed up with the prescriber, while in a 
low-priority case, there would be no time restriction on the intervention being made due to 
the nature of the medication. Although some medication classes have a small number of 
interventions, for example the Antibiotics class, it was still essential for these to be 
represented due to antibiotic stewardship, a principle to limit inappropriate antibiotic use in 
order to ensure that antimicrobial resistance is reduced. 
 
Figure 1: Flow chart to allow classification of intervention into different priorities 
 
 
 
Analysis of the most common medications 
The data was ranked according to the amount of interventions made for each drug, 
irrespective of type or priority. For any medication that had been involved in 15 or more 
interventions, the data was separated. This included 12 drugs and accounted for 50% of the 
data. 
 
Correlation with emergency admission statistics 
Data was collected independently by the MDT for each year over the course of the Quest for 
Quality pilot for hospital admissions. These figures were compared to the total medication 
reviews conducted each year using the Spearman’s rank correlation test. These figures 
represent the influence that the whole team had on the hospital admission rates, not just 
through medication review, but also taking into account telecare health, a system that allows 
real-time monitoring of patient vital signs. Therefore, the percentage of emergency hospital 
admissions that relate to medication errors must be calculated; a figure of 6.5% 
(Pirmohamed, 2004) was used for this, which is the best estimate according to the literature. 
No data was eliminated from this part of the analysis, as it was only the outcome of the 
intervention that would be correlated and not the follow-up. 
 
 
Findings 
 
Overall, the average number of reviews conducted increased over the time period. However, 
when looking at the average interventions made per patient visit (2.8), only 20.8% were 
acted on. Furthermore, out of a total of 401 interventions, 43.4% were not actioned and 
35.8% had unknown outcomes, indicating an issue with uptake by prescribers and follow-up. 
 
Classification of interventions and implications of trends 
Interventions were classified in multiple ways to allow analysis of trends in the data. By 
looking at 150 patients where there were 330 medication changes, it was shown that the 
percentage of medications added to a patient’s regime (7.6%) was much lower than the 
amount of medications removed (71.2%) and medications switched (21.2%). These 
percentages fit with the Elderly Care Guidance that medication regimes should be reduced 
as much as possible (Jones et al., 2014) and that any inappropriate medications should be 
stopped. 
 
Surgeries and care homes 
To establish trends across the 21 surgeries and 20 care homes involved, the data was 
separated. This was an important factor, as finding an issue at one site may skew results for 
the whole data set. Three sites made the largest contribution; this could be due to patients 
having very complicated conditions, giving rise to issues with polypharmacy and multiple 
interventions being made on one patient. The number of interventions undertaken in each 
location varied, ranging from 1 to 67 for care homes, depending largely on the proximity of 
the site to the MDT, and from 1 to 69 for the surgeries, a factor dependent on the surgery 
catchment area. Overall, there was no single care home or surgery responsible for skewing 
the percentages, although there were a number of sites that had a 100% uptake or 100% 
not actioned; these locations accounted for only a small number of reviews.  
 
Most common medications involved in interventions 
Looking at the most common medications involved in interventions (Figure 2), it is clear that 
many involve the same class of drug, for example, the addition of Adcal D3 (given to the 
elderly for the prevention of osteoporosis) or the removal of statins, including atorvastatin 
and simvastatin, a common class for those over the age of 65. The 12 most common drugs 
had equally low intervention acceptance rates, with atorvastatin having particularly low 
action rates and furosemide the highest percentage.  
 
Figure 2: Number of add, switch or remove interventions for most common medications 
 
 
An example of medication commonly found in the elderly population is proton pump 
inhibitors such as lansoprazole and omeprazole. In the data, there was a trend for switching 
omeprazole to lansoprazole; this could be due to research that lansoprazole has a better 
effect on oesophageal acidity (Janczewska, Sagar, & Sjosted, 1998), or related to cost. 
Omeprazole was also being changed to ranitidine, or, on some occasions, Losec MUPS, a 
modified dosage formulation of omeprazole. 
 
The statins prescribed for hyperlipidaemia, including atorvastatin and simvastatin, are 
another group of common medications. The majority of interventions in this category 
involved removal of the statin (Figure 2), except for one, where simvastatin was swapped for 
atorvastatin, a higher-potency drug in the same class; this is a simple intervention that 
means the statin can be taken at any time during the day. The Stopp/Start toolkit (NHS 
Cumbria, 2013), a key piece of guidance for prescribing in the elderly, states that a statin 
should be started in the elderly with a history of coronary, cerebral or peripheral vascular 
disease with a life expectancy of over five years. The majority of patients will be taking 
statins as long-term therapy; therefore, patients entering these care homes are likely to be 
already taking a statin. Due to the nature of the patients, their complications and average life 
expectancy, the removal of statins is likely to be due to the associated risks, such as 
rhabdomyolysis.  
 
Another common medication is buprenorphine, which can be used in opiate addiction and is 
prescribed for chronic pain in the elderly. The majority of the formulations are transdermal 
patches so the dose release can be better controlled (Vadivelu & Hines, 2008). A Larger 
proportion of the data is removal of Buprenorphine or switching to lower doses, which is 
beneficial to the patient due to withdrawal and dependence issues.  
 
Alendronic acid, a bisphosphate prescribed in the elderly to reduce the 10-year risk of 
osteoporosis, is commonly involved in interventions. A known adverse effect is the risk of 
atypical stress fractures (Welsh Medicines Resource Centre, 2010) with long-term therapy 
(MHRA, 2011). In this study, 93% of the interventions were removals (Figure 2), which is as 
expected due to the potential risk being greater than the benefit. 
 
The number of interventions was highest for Adcal D3, which contains calcium and vitamin 
D, contributing to bone and teeth health, which is an issue in the elderly. The majority of 
these interventions involved the addition of the caplets or chewable tablets. The guidance 
used by the MDT provides explanations for the interventions.  
 
Apart from reasons such as medicines optimisation and safety, some interventions are due 
to patient refusal. This is important, as patient non-adherence is a major issue (Jones et al., 
2014), and a simple intervention can improve the patient’s quality of life and save money. 
 
Intervention priorities and harm minimisation 
The interventions were first classified into BNF categories and then further into the priorities 
according to the flow chart (Figure 1). In the Antibiotics category, the majority of 
interventions were high priority, but the numbers that were actioned and those not acted 
upon were equal. Each group represents a different sample size, for example, the two 
categories Obstetrics, Gynaecology and Urinary Tract Infections and Musculoskeletal and 
Joints both show similar distributions in the priority of interventions made, but because 
Musculoskeletal and Joints is a much larger sample, there were more medium- and low-
priority interventions made overall. The interventions in one of the largest categories, 
Nutrition and Blood, were all classified as low-risk interventions due to the type of 
medications, whereas in Central Nervous System category, the interventions were 
distributed across all the priority levels, with more skewed towards low and medium. 
 
Out of the 801 interventions, there were an equal number with low and medium priority, with 
high-priority interventions making up a much smaller proportion, often due to the timescales 
and risks involved. Examples include bisphosphonates, the benefits of which will be seen 
over a long time period, and topical pain-relieving gels such as diclofenac and ibuprofen, 
where the risk to the patient is minimal. The category with the largest proportion of high-
priority interventions is Antibiotics. This is because making a change to a patient’s treatment 
in this class can result in a very rapid improvement in quality of life and can stop the 
progression of an infection that may result in hospitalisation. An example would be 
trimethoprim stopping hospital admission for a urinary tract infection. Equally, stopping an 
inappropriate course of antibiotics can both reduce the contribution to antibiotic resistance 
and ensure the patient is not experiencing side effects such as nausea and photosensitivity, 
as with, for example, doxycycline (Bryant, Fisher, & Kluge, 1987). Another category 
comprising only low-priority interventions is Nutrition and Blood, which had interventions 
made to Adcal D3 chewable tablets and Calogen Extra Shots due to patient preference. 
These interventions are all low priority, as there is no immediate clinical reason that these 
need to be stopped or changed for the patient. There are a number of possible reasons for 
the lower number of high-priority interventions, such as the patient not being in an acute care 
environment, where conditions may be more serious. Furthermore, due to the nature of high-
risk medication, prescribers tend to be more careful when constructing dosing regimes, so 
fewer interventions will be necessary at a later date. These findings would reduce the 
demand on the surgeries and care homes, as only high-priority interventions would need to 
be considered immediately, while low-risk interventions can be implemented at a time to suit 
the prescriber. 
 
Individual case studies of note 
 
Removal of risperidone 
In one intervention the patient was taking 1g of risperidone at night. The MDT requested that 
this be removed for safety reasons. Risperidone is an antipsychotic used to treat 
schizophrenia and bipolar disorder. This intervention was classified as high priority due to 
the safety aspect, and was neither actioned nor followed up. The drug can also be used to 
treat psychosis symptoms associated with dementia; a warning has been added that 
prescribing it to elderly patients can carry a risk of death (FDA, 2006). 
 
Polypharmacy reduction in multiple patients 
In many cases, there were multiple interventions made for the same patient. One patient 
reviewed during December 2014 had multiple medications stopped, simplifying the 
medication regime considerably (Table 1). A complicated medication regime can be difficult 
to manage in a care home situation; therefore, there are benefits to making sure 
polypharmacy is at a minimum.  
 
Table 1: Medication changes as a result of interventions on a patient during December 2014 
 
 
Addition of Anoro Ellipta 
A resident had Anoro Ellipta added to their regime for reasons of medicine optimisation. 
Anoro Ellipta is a combination therapy long acting 
ß2-adrenergic agonist(LABA) and long-acting muscarinic antagonist (LAMA) used in chronic 
obstructive pulmonary Disease (COPD). Although it is not currently stated as being the 
primary treatment, the National Institute for Health and Care Excellence evidence (NICE, 
2014) states that this treatment is beneficial for a patient where a corticosteroid is 
Medications Stopped Medications Started 
Prednisolone 5mg OD Paracetamol 500mg 10 pack 
Adcal D3 Chewable 56 Pack Doxazocin 4mg tablets 
Omeprazole 20mg  OD Glyceryl Trinitrate 400mcg s/l Spray 
Nefopam 30mg TDS 90 pack Movicol 30 pack 
Doxazocin 4mg m/r Tablets  
Diltiazem 120mg M/R Capsules  
Isosorbide Mononitrate 60mg m/r OD  
Lactulose Solution 500ml  
unsuccessful. It may be that without the intervention from the MDT, this patient would not 
have been prescribed this new drug that could improve the management of the COPD. 
 
Intervention due to safety of dalteparin 
Dalteparin was removed from one patient during a review in June 2015; the patient was 
receiving 10,000 units subcutaneously daily. Dalteparin is low molecular weight heparin used 
as prophylaxis of deep vein thrombosis, pulmonary embolism or venous thromboembolism, 
among other indications. As this is a high-risk drug, there are many reasons why this would 
have been removed, including that the patient had an increased risk of bleeding, or renal 
impairment. This was an essential intervention to ensure patient safety.  
 
Correlation of MDT reviews and hospital admission rates 
The correlation between the hospitalisation rates from Quest care homes and the number of 
reviews conducted was quantified. There is a clear trend that as the number of reviews is 
increasing, the number of hospital admissions is decreasing. This was calculated as 
admissions due to medication-related issues with a figure of 6.5% (MHRA, 2014). In the 
sample, a strong negative correlation (Pearson Correlation=−0.983) can be seen. However, 
due to the sample size, statistical significance could not be determined (CI=95%, 0.119). 
Therefore, in the future it would be beneficial to continue recording hospital admissions, 
giving the possibility of a significant statistical relationship. Overall, there was a 50% 
reduction in admissions over the 17 months in admissions. This is high when compared with 
a reported figure of 16% (Gillespie et al., 2009), but the small amount of evidence and the 
assumption used to estimate the numbers may contribute to this. Although it is not possible 
to draw the conclusion that the MDT has reduced the number of hospitalisations, it is clear 
that conducting regular reviews on patients to make sure they are receiving the correct 
medication has been of benefit. 
 
Interventions not implemented: systems issues or prescriber preference?  
Over the whole data set, only 20% of interventions were known to be implemented, 43% 
were not, and the rest were unknown.  
 
The Quest pharmacist gave various reasons to explain the lack of follow-up on the 
interventions, the main one being that the GPs use different record systems and therefore 
access to follow-up data was limited for the MDT. This occurred in approximately 50–60% of 
the reviews. Another reason is that the interventions were not being received by the correct 
person. This, again, is a major issue for the scheme because if a high-priority intervention 
was missed, a patient could be at risk. For example, in the Cardiovascular category, only 
three high-priority interventions were actioned. These included the use of digoxin, a cardiac 
glycoside with a narrow therapeutic window and high-risk of ADRs, and rivaroxaban, an oral 
anticoagulant with no approved antidote should the patient overdose. If these interventions 
were not implemented, there could be serious consequences for the patients. With regard to 
the interventions involving addition, switching and removal, almost half of the interventions in 
each category were known not to be actioned. This indicated two possible issues, one being 
that the prescriber and the MDT are following different guidance, which could explain the low 
uptake in statin intervention. The second issue relates to the number of interventions made: 
it is not feasible to action all in the time available at GP surgeries. It was stated by the Quest 
pharmacist after the MDT meeting that the pharmacist will write to the GPs around the time 
of intervention, but due to the nature of discussing this with the GP in writing, a better system 
of follow-up, with systems access, may be required. In other studies, this rate of uptake has 
been found to be 45% (Roberts et al., 2008), and this is something that needs further 
investigation.  
 
 
 
 
 
Research implications 
The Quest for Quality scheme has already been continued for the future. 
 
Patient benefit 
The residents of the care homes involved have benefited not only from the interventions 
made by the MDT but also from the use of telecare health. Due to the nature of the patients 
residing in these homes, they often have complicated medical history and multidrug regimes. 
Therefore, any input from a health professional in an environment where time is normally 
restricted allows for an increase in the quality of care.  
 
Positive contribution of the Quest pharmacist 
During the MDT meetings, both the pharmacist and the consultant made suggestions of 
interventions for the patient and this was then discussed by the matron, care home staff and 
the patient if they were present. Due to the structure of these meetings, it is impossible to 
state that the interventions are a direct result of the pharmacist being involved and therefore, 
a literature figure was used to estimate the percentage of hospital admissions that were due 
to medication issues. As the number of interventions increases, the number of medication-
related hospital admissions decreases. It could therefore be inferred that the pharmacist has 
potentially had a positive impact on the MDT and the quality of the interventions, though 
future specific research would be needed for proof of this. Although the contribution of the 
Quest pharmacist cannot be proven, it is obvious from the types of interventions made that 
the particular expertise in medications and optimisation of medication regimes will prove 
valuable to the MDT. 
 
Originality and value 
This paper has allowed the interventions made by the MDT to be classified and analysed, 
proving the value of their introduction in the Quest for Quality scheme. The analysis has 
allowed issues to be raised with the scheme and suggestions for the future have been made 
as a result.  
 
As Quest for Quality was a new scheme, this paper has discussed results not previously 
published. For the MDT directly, it can provide suggestions to address some of the issues in 
data collection and follow-up. Furthermore, this paper will be beneficial to similar projects in 
the future, and goes some way to proving the justification for pharmacy involvement in an 
MDT. 
 
Research limitations  
The data analysis demonstrates the apparent benefits of the MDT. This is evidenced in the 
individual case study interventions that have been described and in the number of 
interventions made. However, it is difficult to prove any significant statistical relationships 
unless this data continues to be collected. Due to the lack of inclusion of the elderly 
population in clinical trials and medical research, it is difficult to state the long-term benefits 
of the interventions made. However, such benefits could be demonstrated by looking at 
other health data collected from patients by the telecare health system, which would give a 
long-term view of the effectiveness of the intervention. Although the quantity of data 
collected for this study was large and from a wide distribution of patients across Quest care 
homes, most of the records were incomplete, so had to be excluded from parts of the 
analysis. As the information had been collected in previous years, it was beyond the control 
of the research and depended on how much information the MDT was able to collect. 
Therefore, the methods of collection are something to consider in the future. The scheme 
was also conducted in an area involving selected Quest care homes, and hence, the data 
could not be generalised to show that an MDT would be beneficial in all situations. Although 
the limitations have been listed, the extent to which they affect the results is small; even if a 
true statistical significance cannot yet be proven due to lack of data, there is still a positive 
impact on care. 
 
Future suggestions 
There are a number of ways that the uptake of interventions could be improved in the future. 
A method that avoids the problems of systems that were not accessible to all parties would 
need to be used. If the study was conducted prospectively instead of retrospectively, a 
number of methodology improvements could be made. The flow chart would still be used to 
classify interventions, but it would need to be adapted to include factors such as 
comorbidities and clinical aspects relevant at the time of intervention. Also concerning data 
collection, a small number of care homes should be included, and each intervention could 
then be traced back to the original patient. An option to solve the issues of follow-up could 
be to develop a system to which all GPs and other health care professionals would transfer 
details, meaning that patients would be trackable. This would not only be expensive but also 
take a lot of time and would be resource intensive. If the flow chart system was followed and 
each intervention was classified, it would mean that interventions would be easier to follow 
up, as only the high-priority interventions would need to be checked. They would be checked 
as soon as possible, either by a phone call to the prescriber or by an internal programme of 
intervention sheets, where the care home could let the MDT know that an intervention had 
been implemented or rejected, or that it needed further discussion with the prescriber. 
 
One important theme that has been repeated is that medication reviews in care homes are 
much more effective when they involve both a team of health care professionals and staff 
who know the patients’ medical history. Therefore, in the future this should be continued. 
The Quest for Quality scheme was an undoubted success, and has therefore been 
recommissioned for the future with the hope of gaining a permanent position for a 
pharmacist. 
 
Conclusion 
 
Not only did the Quest for Quality scheme involve a large number of reviews taking place, 
but appropriate and significant interventions resulted, with the input of health care 
professionals and the patients themselves, allowing the best decision to be made.  
 
The characterisation of the interventions showed the most significant areas in which 
interventions were being made, and these correlated with the areas of common medical 
problems in the elderly.  
 
The types of interventions made showed that the MDT were successful in reducing 
polypharmacy in the elderly by removing more medications than were added, and also by 
switching medicines, thereby reducing the complication of patients’ medical regimes, a 
common reason for non-adherence and ADRs.  
 
After developing a way to classify the priorities of interventions, it was shown that the 
majority were low and medium priority. This leads to the possibility of a system of notification 
in the future, based on priority; for cases where it is essential that the intervention is 
implemented quickly, a method of communication would exist between the parties involved.  
 
No significant statistical relationship was proven between the reduction in hospital admission 
rates and the reviews conducted, as a result of factors beyond the control of the study. 
Nevertheless, it was clear that the scheme is likely to have contributed to this reduction in 
number, and it was suggested that this recording of numbers could be continued in the 
future and differentiated to show the long-term impact of both the MDT and, more 
specifically, pharmacy.  
 
The expertise of the pharmacist involved had some degree of impact on the interventions 
made, along with the clinician. The interventions not only followed the appropriate guidance 
on treatment option, but also used evidence-based medicine principles to provide the most 
appropriate treatment option to the patient.  
 
The major limitations in the research were out of the author’s control due to the nature of the 
retrospective analysis. Suggestions made for the future included focusing on a smaller group 
of patients and being able to follow up on these interventions, documenting the impact using 
other monitoring data. The development of a specific system allowing the follow-up of each 
intervention would be beneficial in the future, making sure that the high-quality and 
appropriate interventions that the MDT are making are not wasted. More discussion is 
needed between the MDT and prescribers to establish whether there are any reasons why 
common specific interventions are not being actioned, and how this can be solved in the 
future.  
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